Department of Pharmacy, Kurume University Hospital, Fukuoka, Japan.
Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Fukuoka, Japan.
J Gastroenterol Hepatol. 2023 Jul;38(7):1140-1147. doi: 10.1111/jgh.16168. Epub 2023 Mar 16.
This study aimed to investigate whether telephone follow-up by clinical pharmacists for unresectable hepatocellular carcinoma (HCC) patients treated with lenvatinib (LEN) contributes to improved adherence and treatment duration for LEN.
This retrospective study enrolled 132 patients with HCC who were treated with LEN. The patients were classified into non-telephone follow-up (n = 32) or telephone follow-up groups (n = 100) [the latter group was further classified into family-pharmacist (FP) telephone follow-up (n = 18), or hospital family-pharmacist (HFP) telephone follow-up (n = 82) groups].
The progression-free survival (PFS) in the telephone follow-up group was significantly higher than that in the non-telephone follow-up group (PFS 6.1 months vs 3.7 months, P = 0.001, respectively). Although treatment duration was significantly longer in the telephone follow-up group than in the non-telephone follow-up group [median treatment duration: 10.4 months vs 4.1 months, P = 0.001, respectively.], no significant differences were noted between the HFP telephone follow-up group and FP telephone follow-up groups (10.3 months vs 13.3 months, P = 0.543). Self-interruption and adverse-event discontinuation in the HFP-telephone follow-up group were significantly lower than those in the FP-telephone and non-telephone groups (0% vs 11.1% vs 18.8%; P < 0.001, 25.6% vs 33.3% vs 53.1%; P = 0.022, respectively).
Telephone follow-up contributes to prolonged treatment duration for LEN in patients with HCC treated. Moreover, telephone follow-up with an HFP may further improve treatment adherence.
本研究旨在探讨临床药师对接受仑伐替尼（LEN）治疗的不可切除肝细胞癌（HCC）患者进行电话随访是否有助于提高 LEN 的依从性和治疗持续时间。
本回顾性研究纳入了 132 名接受 LEN 治疗的 HCC 患者。患者被分为非电话随访（n=32）或电话随访组（n=100）[后者进一步分为家庭药师（FP）电话随访（n=18）或医院家庭药师（HFP）电话随访组（n=82）]。
电话随访组的无进展生存期（PFS）明显长于非电话随访组（PFS 6.1 个月 vs 3.7 个月，P=0.001）。虽然电话随访组的治疗持续时间明显长于非电话随访组[中位治疗持续时间：10.4 个月 vs 4.1 个月，P=0.001]，但 HFP 电话随访组与 FP 电话随访组之间无显著差异[10.3 个月 vs 13.3 个月，P=0.543]。HFP 电话随访组的自行中断和因不良事件停药的发生率明显低于 FP 电话随访组和非电话随访组（0% vs 11.1% vs 18.8%；P<0.001，25.6% vs 33.3% vs 53.1%；P=0.022）。
电话随访有助于延长 HCC 患者接受 LEN 治疗的持续时间。此外，HFP 的电话随访可能进一步提高治疗依从性。
